Table 1.
HBV patient characteristics and outcome of evaluation
| N = 50 (100%) | |
|---|---|
| Sex | |
| Male | 22 (44%) |
| Female | 28 (56%) |
| Age (years) (mean ± SD) | 48 ± 9.7 |
| Migrational background | |
| Dutch / WE | 4 (8%) |
| EE/EA | 12 (24%) |
| NA | 2 (4%) |
| SSA | 7 (14%) |
| SEA | 23 (46%) |
| LA | 2 (4%) |
| ALT (U/l) (mean + SD) combined with HBV DNA levels (IU/mL) | |
| Normal (0-34 U/l) and HBV DNA < 2.0 · 104 | 44 (88%) |
| ALT >1xULN and HBV DNA < 2.0 · 104 | 3 (6%) |
| ALT >1xULN and HBV DNA > 2,0 · 104 | 3 (6%) |
| Fibrosis stage | |
| Unknown | 2 (4%) |
| F0-F1 | 45 (90%) |
| F2-F3 | 3 (6%) |
| Management advice | |
| No Follow-up needed | 3 (6%) |
| ALT levels every 6-12 months | 25 (50%) |
| ALT levels and HCC screening every 6-12 months | 14 (28%) |
| Strict follow-up every 3-6 months | 5 (10%) |
| Antiviral therapy | 3 (6%) |
WE Western Europe, EE Eastern Europe, EA EuroAsia, NA North Africa, SSA Sub-Saharan Africa, SEA South East Asia, LA Latin America, ALT Alanine-aminotransferase, ULN Upper limit of normal, HCC Hepatocellular carcinoma